![Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/df97e815-5933-42d8-9d96-69b56b1419d1/gr2.jpg)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
![Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/20656edb-004d-431e-af4b-0e09c258f296/gr1.gif)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology
![Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ... Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fa133f3d-73da-45fe-8ea3-4842ec649559/gr1_lrg.jpg)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ...
![Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/caffdea1-0e9e-494e-b853-27fc4e390917/gr1_lrg.gif)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology
![Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - The Lancet Oncology Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/367b1f6d-8ede-4053-b958-621f015d6cb2/gr1.gif)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - The Lancet Oncology
![Next-Generation Anti–HER2-Antibody Drug Conjugates: Extending the Actionability to “HER2-Low” Breast Cancer Next-Generation Anti–HER2-Antibody Drug Conjugates: Extending the Actionability to “HER2-Low” Breast Cancer](https://dailynews.ascopubs.org/do/10.1200/ADN.19.190401/full/dn19_ee_her2_t1.jpg)
Next-Generation Anti–HER2-Antibody Drug Conjugates: Extending the Actionability to “HER2-Low” Breast Cancer
![ADC Drug DS-8201 Shows Strong Efficacy in Patients with Low HER2 Breast Cancer Expression – Creative Biolabs ADC Blog ADC Drug DS-8201 Shows Strong Efficacy in Patients with Low HER2 Breast Cancer Expression – Creative Biolabs ADC Blog](https://www.creative-biolabs.com/blog/adc/wp-content/uploads/2018/12/adc-12-3.jpg)
ADC Drug DS-8201 Shows Strong Efficacy in Patients with Low HER2 Breast Cancer Expression – Creative Biolabs ADC Blog
![The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers - Annals of Oncology The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ea1812aa-cbc5-4a7d-bdff-bafa5f1b499a/gr1_lrg.jpg)
The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers - Annals of Oncology
![Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response Rates and Disease Control Rates » ADC Review Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response Rates and Disease Control Rates » ADC Review](https://adcreview.com/wp-content/uploads/2018/01/Screen-Shot-2018-01-02-at-6.53.46-PM-1024x587.png)
Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response Rates and Disease Control Rates » ADC Review
![Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ... Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b7fd0ce4-cdbf-42ea-9074-d1d634a0b59c/gr2.jpg)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ...
![Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/09e91b7b-b392-4f4c-9362-d016c3fd70cf/gr1_lrg.gif)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
![Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/af1f1080-b82a-4eaa-a046-6e01b0040308/gr1.gif)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
![Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review](https://www.adcreview.com/wp-content/uploads/2018/12/clinical-trials-696x451.jpg)
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review
![Antitumor immunity caused by combination of DS-8201a and anti-CTLA-4... | Download Scientific Diagram Antitumor immunity caused by combination of DS-8201a and anti-CTLA-4... | Download Scientific Diagram](https://www.researchgate.net/publication/336200688/figure/fig4/AS:809389707493376@1569984952526/Antitumor-immunity-caused-by-combination-of-DS-8201a-and-anti-CTLA-4-antibody-Mice-cured.png)
Antitumor immunity caused by combination of DS-8201a and anti-CTLA-4... | Download Scientific Diagram
![Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review](https://adcreview.com/wp-content/uploads/2017/08/gang2-1024x571.png)
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review
![Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review](https://adcreview.com/wp-content/uploads/2016/10/gang3-1024x609.png)